Recent Posts
Social•Feb 17, 2026
Bispecific Autoimmune Therapies Set to Transform 2024
"Dual Wielding in I&I: A Pivotal Year Ahead" - new blog - Atlas EIR Cody Tranbarger with a tour de force on the bispecific opportunities in autoimmune... https://t.co/StQJX0vgfx
By Bruce Booth
Social•Feb 12, 2026
Biotech IPOs Deliver Median -15% Return, Outperforming Losses
Humbling 30 year Biotech stats shared by @verdadcap in a recent report: Just over 1,000 biotechs hit $200M mkt cap at some point. Of those, 67% have lost value (had cumulative negative returns), vs 48% for all other US companies....
By Bruce Booth
Social•Feb 11, 2026
Scientists Overstate Precision by Ignoring Significant Figures
Pet peeve: why do "scientists" forget about the concept of significant figures? Happens all the time, in biotech & beyond. Too many decimal places scream lack of credibility. "Sig figs" is a simple concept: measurement readings should not push beyond instrument...
By Bruce Booth
Social•Jan 14, 2026
Decade‑Old Myths Still Fuel JPM Healthcare Talk
A dozen years old, but curious how many of these little lies are still told around the #JPM26 conference.... "Top 10 Little White Lies Told At The JP Morgan Healthcare Conference" https://t.co/0er4Beffn3
By Bruce Booth
Social•Jan 11, 2026
Biotech Funding Hits Record Levels in January
Biotech capital markets are clearly open for business: $2.6B in public FOPO so far in January, the most ever pre-JPM conference. Private VC financings of over >$2B in the same period. Investors clearly have cash to put to work......
By Bruce Booth
Social•Jan 11, 2026
PBMs and GPOs Inflate Drug Prices, Hide Billions
“Bullshit” — The New Way Health Giants Hide Billions" https://t.co/6PcmoY1pmh This PBM GPO investigative story makes my blood boil... these intermediaries are why the list-to-net spread for many drugs is over 50% in the US... siphoning off dollars at the expense of...
By Bruce Booth
Social•Jan 8, 2026
Timing Pays: Ventyx Deal Rewards Early IPO Investors
Ventyx $VTYX acquired by Lilly $LLY for $14/share or $1.2B valuation. IPO'd in 2021 at $16/share, around $800M market cap. So acquisition is like ~15% below the IPO price but ~50% above the IPO valuation Great pivot from TYK2 lead program...
By Bruce Booth